Navidea biopharmaceuticals announces the notice of allowance for u.s. patent application for key component of the company's cancer immunotherapy pipeline

Dublin, ohio--( business wire )--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has received a notice of allowance from the u.s. patent and trademark office for its patent application titled, “compositions and methods for altering macrophage phenotype (us application #16/832,620).” broadly, this patent covers the ability of navidea's constructs to stimulate the body's immune response against tumors through targeted delivery of payloads (e.g., doxorubicin, paclitaxel, and bisphosphonates) that change the nature of macrophages to make them more proinflammatory. these constructs have demonstrated the ability to rally an immune response against tumors and make other therapies work more effectively against those tumors in preclinical studies. if confirmed in clinical trials, the ability to increase the efficacy of cancer therapeutics by harnessing the body's immune system could bring significant benefits to patients.
NAVB Ratings Summary
NAVB Quant Ranking